Physician profile
Christopher Goodman
NPI 1801327358
$810.47
in general payments reported to CMS, 2019-2025
15 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.72 · 2021: $50.89 · 2023: $293 · 2024: $173 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $744.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $179.57 | 2023-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $116.70 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $105.46 | 2024-2025 | Airsupra, Breztri |
| Dexcom, INC. | $60.30 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $57.30 | 2021-2025 | Evenity, Prolia, Prolia |
| Abbott Laboratories | $52.16 | 2023-2025 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $47.88 | 2023 | Injectafer |
| Abbvie INC. | $35.62 | 2021-2025 | |
| Astellas Pharma US INC | $34.30 | 2021-2024 | Veozah |
| Electromed, INC. | $23.96 | 2024 | Smartvest |
| Sanofi Pasteur INC. | $23.50 | 2023 | |
| Baxter Healthcare | $23.06 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Glaxosmithkline, LLC. | $18.33 | 2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $17.61 | 2023 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $14.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.